Shae Chambers
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shae Chambers has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Victoria P. Werth
Corporal Michael J. Crescenz Veterans Affairs Medical Center Philadelphia, Philadelphia, Pennsylvania, USA; Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
6 shared publications Aretha On
University of Pennsylvania
4 shared publicationsHammad Ali
Department of Dermatology Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
3 shared publications- Hammad Ali
University of Pennsylvania
3 shared publications Lais Lopes Almeida Gomes
Department of Dermatology Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA
3 shared publications- Touraj Khosravi-Hafshejani
Department of Dermatology and Skin Science, University of British Columbia, Vancouver, BC, Canada
3 shared publications
Latest Publications
- 24 April 2026
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (8) , 1810-1811
Reply
- 24 December 2025
- Published by SAGE Publications in Lupus
- Vol. 35 (2) , 218-220
Barriers to clinical trial access among Black lupus patients
- 24 December 2025
- Published by SAGE Publications in Lupus
- Vol. 35 (2) , 218-220
Barriers to clinical trial access among Black lupus patients
- Open Access
- 15 September 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (9) , 1164-1167
Atypische Infektionen während der Kombinationstherapie mit Anifrolumab und anderen Immunsuppressiva bei Patientinnen mit Lupus erythematodes: Eine Fallserie
- 15 September 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (9) , 1164-1167
Open AccessAtypische Infektionen während der Kombinationstherapie mit Anifrolumab und anderen Immunsuppressiva bei Patientinnen mit Lupus erythematodes: Eine Fallserie
- 24 July 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 779-781
Normal muscle enzyme levels in classic dermatomyositis: implications for clinical trial endpoints
Muscle involvement in dermatomyositis can present without muscle enzyme elevations in 26–48% of patients. These findings are important to acknowledge in order to interpret muscle enzyme testing within the broader clinical context.
- 24 July 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (4) , 779-781
Normal muscle enzyme levels in classic dermatomyositis: implications for clinical trial endpoints
Muscle involvement in dermatomyositis can present without muscle enzyme elevations in 26–48% of patients. These findings are important to acknowledge in order to interpret muscle enzyme testing within the broader clinical context.
- Open Access
- 1 July 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001637
Dyspigmentation and scarring in cutaneous lupus erythematosus
Objective: No studies have investigated the incidence and correlation of scarring and dyspigmentation across all cutaneous lupus erythematosus (CLE) categories and subtypes. As better characterisation of such symptoms may impact how clinicians document disease damage as well as manage patients’ expectations on their disease course, we set out to investigate the relationship between dyspigmentation and scarring in CLE further. Methods: We conducted a cross-sectional review of our IRB-approved CLE database at the University of Pennsylvania. Patients were divided by category and chronic CLE (CCLE) subtype. Dyspigmentation and scarring were quantified using the CLE Disease Area and Severity Index damage score. Data on dyspigmentation and scarring were captured from the patient visit where dyspigmentation was highest. Results: Dyspigmentation and scarring significantly differed between CLE categories and CCLE subtypes. Across categories, CCLE had the highest medians for dyspigmentation and scarring. Across CCLE subtypes, discoid lupus erythematosus (DLE) had the highest medians for dyspigmentation and scarring. Positive correlations for dyspigmentation and scarring were seen in CCLE, DLE and LE panniculitis. Conclusions: Dyspigmentation and scarring correlation differences highlight the importance of accurate assessment and documentation of both elements of damage as well as classification of CLE category and subtype. Our results reflect important differences in the CLE categories and CCLE subtypes which may be helpful for clinicians and patients as they navigate the course of the disease.
- 1 July 2025
- Published by BMJ in Lupus Science & Medicine
- Vol. 12 (2) , e001637
Open AccessDyspigmentation and scarring in cutaneous lupus erythematosus
Objective: No studies have investigated the incidence and correlation of scarring and dyspigmentation across all cutaneous lupus erythematosus (CLE) categories and subtypes. As better characterisation of such symptoms may impact how clinicians document disease damage as well as manage patients’ expectations on their disease course, we set out to investigate the relationship between dyspigmentation and scarring in CLE further. Methods: We conducted a cross-sectional review of our IRB-approved CLE database at the University of Pennsylvania. Patients were divided by category and chronic CLE (CCLE) subtype. Dyspigmentation and scarring were quantified using the CLE Disease Area and Severity Index damage score. Data on dyspigmentation and scarring were captured from the patient visit where dyspigmentation was highest. Results: Dyspigmentation and scarring significantly differed between CLE categories and CCLE subtypes. Across categories, CCLE had the highest medians for dyspigmentation and scarring. Across CCLE subtypes, discoid lupus erythematosus (DLE) had the highest medians for dyspigmentation and scarring. Positive correlations for dyspigmentation and scarring were seen in CCLE, DLE and LE panniculitis. Conclusions: Dyspigmentation and scarring correlation differences highlight the importance of accurate assessment and documentation of both elements of damage as well as classification of CLE category and subtype. Our results reflect important differences in the CLE categories and CCLE subtypes which may be helpful for clinicians and patients as they navigate the course of the disease.
- Open Access
- 4 June 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (8) , 1799-1800
Clinical Images: Subcutaneous panniculitis‐like T cell lymphoma
- 4 June 2025
- Published by Wiley in Arthritis & Rheumatology
- Vol. 78 (8) , 1799-1800
Open AccessClinical Images: Subcutaneous panniculitis‐like T cell lymphoma
- Open Access
- 23 May 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (9) , 1164-1167
Atypical infections during combination therapy with anifrolumab and other immunosuppressives in patients with lupus erythematosus: A case series
- 23 May 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (9) , 1164-1167
Open AccessAtypical infections during combination therapy with anifrolumab and other immunosuppressives in patients with lupus erythematosus: A case series
- Open Access
- 15 May 2025
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 10 (2) , NP1-NP4
Isolated scleroderma of the lower extremities misdiagnosed as lymphedema and presenting with scleroderma renal crisis
Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by progressive fibrosis, vasculopathy, and immune dysregulation. The disease commonly presents with Raynaud’s phenomenon and skin thickening, commonly of the upper limb. Isolated lower extremity presentation is uncommon and often misdiagnosed. This diagnostic uncertainty may lead to delayed recognition and increased morbidity, particularly when SSc mimics lymphedema in the early stages. We report a case of a 61-year-old female who initially presented with lower extremity swelling and was misdiagnosed with primary lymphedema. Despite treatment with diuretics and compression therapy, her symptoms progressed to involve her upper extremities, prompting further evaluation. Physical examination revealed non-pitting lower extremity scleroderma, sclerodactyly, puffy hands, and nailfold capillary abnormalities. Laboratory workup was positive for anti-RNA polymerase III antibodies, a marker associated with an increased risk of scleroderma renal crisis. The patient developed scleroderma renal crisis after a delayed diagnosis, necessitating hospital admission and initiation of angiotensin-converting enzyme inhibitors. This case highlights the challenges in distinguishing early lower extremity SSc from lymphedema. Early identification of atypical SSc presentations is critical to be cognizant of life-threatening complications such as scleroderma renal crisis. Clinicians should maintain a high index of suspicion for SSc in patients with persistent non-pitting lower extremity swelling, skin thickening, and abnormal capillaroscopy findings, even in the absence of initial upper limb involvement.
- 15 May 2025
- Published by BMJ in Journal of Scleroderma and Related Disorders
- Vol. 10 (2) , NP1-NP4
Open AccessIsolated scleroderma of the lower extremities misdiagnosed as lymphedema and presenting with scleroderma renal crisis
Systemic sclerosis (SSc) is a chronic autoimmune disorder characterized by progressive fibrosis, vasculopathy, and immune dysregulation. The disease commonly presents with Raynaud’s phenomenon and skin thickening, commonly of the upper limb. Isolated lower extremity presentation is uncommon and often misdiagnosed. This diagnostic uncertainty may lead to delayed recognition and increased morbidity, particularly when SSc mimics lymphedema in the early stages. We report a case of a 61-year-old female who initially presented with lower extremity swelling and was misdiagnosed with primary lymphedema. Despite treatment with diuretics and compression therapy, her symptoms progressed to involve her upper extremities, prompting further evaluation. Physical examination revealed non-pitting lower extremity scleroderma, sclerodactyly, puffy hands, and nailfold capillary abnormalities. Laboratory workup was positive for anti-RNA polymerase III antibodies, a marker associated with an increased risk of scleroderma renal crisis. The patient developed scleroderma renal crisis after a delayed diagnosis, necessitating hospital admission and initiation of angiotensin-converting enzyme inhibitors. This case highlights the challenges in distinguishing early lower extremity SSc from lymphedema. Early identification of atypical SSc presentations is critical to be cognizant of life-threatening complications such as scleroderma renal crisis. Clinicians should maintain a high index of suspicion for SSc in patients with persistent non-pitting lower extremity swelling, skin thickening, and abnormal capillaroscopy findings, even in the absence of initial upper limb involvement.
- 2 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (3) , 558-560
Erythema and scale in cutaneous lupus erythematosus significantly impacts patient quality of life and disease course impression
Our study seeks to further characterize the impact of CLASI-A erythema and scale on patient quality of life in a larger multicentre cohort study. We found that both erythema and scale were associated with several PROMs, both at baseline and over time, most notably with patient impressions of disease progression. These findings justify the inclusion of erythema and scale in CLASI-A scoring and has important implications for future treatment directions, as no accepted measure of disease severity currently exists for cutaneous lupus erythematosus.
- 2 May 2025
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 193 (3) , 558-560
Erythema and scale in cutaneous lupus erythematosus significantly impacts patient quality of life and disease course impression
Our study seeks to further characterize the impact of CLASI-A erythema and scale on patient quality of life in a larger multicentre cohort study. We found that both erythema and scale were associated with several PROMs, both at baseline and over time, most notably with patient impressions of disease progression. These findings justify the inclusion of erythema and scale in CLASI-A scoring and has important implications for future treatment directions, as no accepted measure of disease severity currently exists for cutaneous lupus erythematosus.